Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$30.03 USD

30.03
41,269,717

+0.53 (1.80%)

Updated Jul 17, 2024 04:01 PM ET

After-Market: $29.99 -0.04 (-0.13%) 4:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (163 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Arena Ends Study on Extended Release Formulation of PAH Drug

Arena Pharmaceuticals, Inc. (ARNA), announced that it has completed an early-stage study comparing the once-daily, extended release (XR) formulation of its experimental pulmonary arterial hypertension (PAH) candidate, ralinepag, with its twice-daily immediate release (IR) formulation.

    Sarepta Looks to Focus on Exondys 51 & DMD Pipeline in 2017

    We issued an updated research report on Cambridge, MA-based Sarepta Therapeutics, Inc. (SRPT) on Jun 28.

      Zacks Industry Outlook Highlights: Johnson & Johnson, Incyte, Pfizer, Novartis and AstraZeneca

      Zacks Industry Outlook Highlights: Johnson & Johnson, Incyte, Pfizer, Novartis and AstraZeneca

        Arpita Dutt headshot

        M&As, Rich Pipelines & Catalyst Rich 2017 to Drive Pharma Stocks

        The biotech sector's fundamentals remain strong.

          Merck's CETP Inhibitor Reduces CV Risk in Phase III Study

          Merck & Co., Inc. (MRK) announced that a large late-stage cardiovascular outcomes study (REVEAL) evaluating anacetrapib, a cholesterol-lowering medicine, met the primary endpoint by reducing cardiovascular (CV) risk.

            AstraZeneca's Faslodex Recommended by CHMP for 1st Line Use

            AstraZeneca PLC (AZN) announced that the CHMP of the European Medicines Agency has adopted a positive opinion recommending the marketing authorisation of Faslodex for 1st-line treatment for postmenopausal women with HR+ advanced breast cancer.

              Sanofi/Regeneron's Kevzara Gets Marketing Approval in EU

              Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) announced that the European Commission has granted marketing approval to its rheumatoid arthritis (RA) drug Kevzara.

                Epizyme Progressing Well on Two Lead Pipeline Candidates

                We issued an updated research report on Epizyme, Inc. (EPZM) on Jun 23, 2017.

                  Eric Dutram headshot

                  Stocks to Fight Cancer: Why Immunotherapy Is a Gamechanger

                  This podcast takes a closer look at the world of cancer research, and in particular, that of immunotherapy. I have guest Brad Loncar on to discuss this market and a few promising candidates to watch in this area, check it out for more info on this interesting biotech segment!

                    Stock Market News for June 22, 2017

                    Energy shares continued to decline on Wednesday, sending the Dow and the S&P 500 lower

                      Merck's Keytruda on a Roll: Can it Retain the Momentum?

                      As demand for immuno-oncology drugs and their combinations rises, Merck & Co., Inc.'s (MRK) anti-PD-1 therapy, Keytruda, is being touted as a significant top-line driver for this Kenilworth, NJ based pharma giant.

                        Shire's (SHPG) ADHD Drug Mydayis Receives Approval in US

                        Shire Plc (SHPG) announced that the FDA has approved its new attention deficit hyperactivity disorder (ADHD) drug, Mydayis (mixed salts of a single-entity amphetamine product) in patients 13 years and older

                          Small Cancer Biotech Space in Focus, 3 Stocks Up 100% & More

                          The oncology space has always been keenly watched by investors interested in the pharma/biotech sector.

                            Exelixis's Cabometyx Positive for First-Line Kidney Cancer

                            Exelixis, Inc. (EXEL) announced results from an analysis of the data from the phase II trial, CABOSUN evaluating Cabometyx to Sutent for kidney cancer.

                              J&J-AbbVie's Imbruvica Positive in Follow-up Lymphoma Study

                              Johnson & Johnson (JNJ) announced a three-year follow-up data from a late stage study, evaluating its cancer drug Imbruvica against Pfizer's Torisel for treatment of patients with relapsed or refractory mantle cell lymphoma (MCL).

                                The Zacks Analyst Blog Highlights: Chevron, Pfizer, Boeing, 3M and Citigroup

                                The Zacks Analyst Blog Highlights: Chevron, Pfizer, Boeing, 3M and Citigroup

                                  Arpita Dutt headshot

                                  3 Biotech Stocks That More than Doubled Year to Date

                                  Here is a look at Puma (PBYI) and two other biotech stocks that have recorded massive gains so far in 2017.

                                    Arpita Dutt headshot

                                    Pharma Stock Roundup: J&J, Lilly Present Data, Merck Keytruda Study Enrolment Paused

                                    Merck (MRK) paused patient enrolment in a couple of studies being conducted with its anti-PD-1 therapy, Keytruda.

                                      Pfizer (PFE) Buys Exclusive EU Rights to Anti-Fungal Drug

                                      Pfizer, Inc. (PFE) announced a deal to buy exclusive EU commercialization rights to an anti-fungal treatment, Cresemba from Swiss pharma company, Basilea Pharmaceutica Ltd.

                                        Acceleron (XLRN) Kidney Cancer Candidate Fails in Phase II

                                        Acceleron Pharma Inc.'s (XLRN) announced disappointing results from a phase II study evaluating its pipeline candidate dalantercept in combination with Pfizer's (PFE) Inlyta (axitinib) for treatment of advanced renal cell carcinoma (RCC).

                                          Pfizer & Lilly Get Fast Track Designation for Pain Candidate

                                          Pfizer Inc. (PFE) and Eli Lilly and Company (LLY) announced that the FDA has granted fast track designation to their pipeline candidate, tanezumab for the treatment of chronic pain in patients with osteoarthritis (OA) and chronic low back pain (CLBP).

                                            Company News for June 14, 2017

                                            Companies in the News are: LLY,PFE,CAKE,JW.A,CVCO

                                              Merck's Diabetes Drug Meets Primary Endpoint in Key Studies

                                              Merck & Co., Inc. (MRK) and partner Pfizer Inc. (PFE) announced that its pipeline candidate, ertugliflozin, met primary endpoints in two late stage studies evaluating ertugliflozin in adults with Type 2 diabetes.

                                                AbbVie (ABBV) Announced Positive Phase III RA Candidate Data

                                                AbbVie Inc. (ABBV) announced positive top-line results from a phase III study on rheumatoid arthritis candidate, upadacitinib (ABT-494).

                                                  Pfizer's (PFE) Tafamidis Gets Fast Track Status in the U.S.

                                                  Pfizer Inc. (PFE) has been granted with fast track status by FDA for treating patients with transthyretin cardiomyopathy (TTR-CM).